RxDoctor Payments Data

Claire Kim, DO

Family Medicine · Houston, TXNPI 1992048979

Payments from drug & device makers

$5,560in general payments, 2019–2025

Across 306 payments — averaging $18.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$680
  • AstraZeneca$538
  • Lilly USA, LLC$353
  • Abbott$342
  • Boston Scientific$251
  • plus $2K from 38 others

What the payments were for

  • Food & beverage$5,554100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,560 in reported general payments places this provider in the 85th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$69,315
Medicare patients
160
Services billed
768

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide86$149,818
MounjaroTirzepatide68$132,625
FarxigaDapagliflozin Propanediol56$74,678
Xigduo XrDapaglifloz Propaned/Metformin34$52,531
JardianceEmpagliflozin37$45,566
SynjardyEmpagliflozin/Metformin Hcl21$27,535
EliquisApixaban16$23,572
XareltoRivaroxaban20$21,752
MyrbetriqMirabegron16$21,017
Synjardy XrEmpagliflozin/Metformin Hcl12$19,135
GemtesaVibegron14$17,483
Advair HfaFluticasone Propion/Salmeterol11$5,098
Rosuvastatin Calcium292$4,847
SynthroidLevothyroxine Sodium48$3,266
Atorvastatin Calcium354$3,191

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,133$149,81886 claims
Lilly USA, LLCMounjaro$353$132,62568 claims
Boehringer IngelheimJardiance, Synjardy, Synjardy Xr$147$92,23670 claims
AstraZenecaFarxiga$538$74,67856 claims
PfizerEliquis$123$23,57216 claims
Johnson & JohnsonXarelto$66$21,75220 claims
Astellas Pharma US IncMyrbetriq$126$21,01716 claims
Sumitomo Pharma America, Inc.Gemtesa$103$17,48314 claims
AbbVieSynthroid$680$3,26648 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →